CRISPR Therapeutics (CRSP) stock price, revenue, and financials

CRISPR Therapeutics market cap is $9 b, and annual revenue was $719 k in FY 2020

$9 B

CRSP Mkt cap, 29-Jul-2021

$719 K

CRISPR Therapeutics Revenue FY, 2020
CRISPR Therapeutics Net income (FY, 2020)-348.9 M
CRISPR Therapeutics EBIT (FY, 2020)-354.4 M
CRISPR Therapeutics Cash, 31-Dec-20201.2 B
CRISPR Therapeutics EV7.9 B
Get notified regarding key financial metrics and revenue changes at CRISPR TherapeuticsLearn more
Banner background

CRISPR Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.2m41.0m3.1m289.6m719.0k

R&D expense

42.2m69.8m113.8m179.4m266.9m

General and administrative expense

31.1m35.8m48.3m63.5m88.2m

Operating expense total

73.3m105.6m162.1m242.9m355.2m

EBIT

(68.1m)(64.6m)(158.9m)46.7m(354.4m)

EBIT margin, %

(1319%)(158%)(5088%)16%(49296%)

Interest expense

8.1m2.0m5.5m20.6m

Investment income

(36.5m)(1.8m)(4.3m)(5.5m)

Pre tax profit

(22.7m)(66.6m)(164.4m)67.3m(348.1m)

Income tax expense

484.0k1.7m553.0k448.0k809.0k

Net Income

(23.2m)(68.4m)(165.0m)66.9m(348.9m)

CRISPR Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

315.5m239.8m456.6m943.8m1.2b

Accounts Receivable

3.2m2.6m88.0k99.0k144.0k

Prepaid Expenses

1.5m6.0m9.7m43.7m26.1m

Current Assets

320.2m248.4m466.4m987.5m1.7b

PP&E

21.0m18.9m18.5m31.3m42.2m

Total Assets

345.0m271.3m489.0m1.1b1.8b

Accounts Payable

4.6m1.6m5.1m5.9m9.1m

Short-term debt

11.4m

Current Liabilities

22.0m14.5m27.7m57.1m94.3m

Long-term debt

44.1m50.1m

Total Debt

44.1m61.4m

Total Liabilities

112.1m83.5m96.8m127.3m163.7m

Common Stock

1.2m1.2m1.6m1.8m2.3m

Additional Paid-in Capital

288.7m312.0m682.2m1.2b2.2b

Retained Earnings

(57.1m)(125.4m)(291.6m)(224.7m)(573.6m)

Total Equity

232.8m187.8m392.2m939.4m1.7b

Financial Leverage

1.5 x1.4 x1.2 x1.1 x1.1 x

CRISPR Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(23.2m)(68.4m)(165.0m)66.9m(348.9m)

Depreciation and Amortization

925.0k3.0m3.5m4.7m9.2m

Accounts Receivable

(2.8m)531.0k2.5m(11.0k)(45.0k)

Accounts Payable

3.9m(831.0k)12.1m5.0m25.7m

Cash From Operating Activities

(55.3m)(70.1m)(96.2m)56.7m(238.4m)

Purchases of PP&E

(3.0m)(7.8m)(2.8m)(6.7m)(18.4m)

Cash From Investing Activities

31.9m(8.3m)(2.8m)1.3m(541.2m)

Cash From Financing Activities

183.2m2.6m315.9m431.0m1.0b

Net Change in Cash

159.6m(75.8m)216.9m489.0m236.7m

CRISPR Therapeutics Ratios

USDQ3, 2016

Financial Leverage

-4.5 x

CRISPR Therapeutics Employee Rating

3.616 votes
Culture & Values
2.9
Work/Life Balance
3.3
Senior Management
2.7
Salary & Benefits
2.7
Career Opportunities
2.8
Source